Literature DB >> 3092427

Intravesical chemotherapy: in vitro studies on the relationship between dose and cytotoxicity.

M C Walker, J R Masters, C N Parris, P J Hepburn, P J English.   

Abstract

The relative importance of two variables, drug concentration and period of exposure, in relation to the therapeutic potential of intravesical chemotherapy was examined in an experimental system. A human bladder cancer cell line was exposed to a range of concentrations of the four drugs commonly used to treat superficial bladder cancer (adriamycin, epodyl, mitomycin-c, thiotepa) for periods of 30, 60 and 120 min. An exponential relationship was observed between clonogenic cell kill and both drug concentration and period of exposure. Thus, under the experimental conditions employed, cytotoxicity is proportional to dose (i.e. concentration X period of exposure). These two variables are of equal importance in relation to tumor cell kill, indicating that maximum therapeutic benefit may be obtained by using the highest concentration achievable for as long as the patient can retain the instillate, bearing in mind the potential increase in toxicity to the patient and the cost.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3092427     DOI: 10.1007/bf00255832

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  16 in total

1.  A METHOD FOR DIRECT DEMONSTRATION OF PLEUROPNEUMONIA-LIKE ORGANISMS IN CULTURED CELLS.

Authors:  J FOGH; H FOGH
Journal:  Proc Soc Exp Biol Med       Date:  1964-12

2.  New assay for cytotoxic agents in human bladder cancer.

Authors:  K Hagen; J J Daly; H M Kamali; J C Lin; S C Yu; G R Prout
Journal:  Surg Forum       Date:  1979

Review 3.  Intravesical chemotherapy of superficial bladder cancer.

Authors:  B L Lum
Journal:  Recent Results Cancer Res       Date:  1983

4.  The concept of drug dose for in vitro studies with chemotherapeutic agents.

Authors:  K T Wheeler; V A Levin; D F Deen
Journal:  Radiat Res       Date:  1978-12       Impact factor: 2.841

5.  Antibody-mediated neutralization of virus is abrogated by mycoplasma.

Authors:  C Dickson; J Elkington; A Hales; R Weiss
Journal:  Infect Immun       Date:  1980-06       Impact factor: 3.441

6.  Cell population kinetics - experimental methods and their in vivo relevance for human cancer chemotherapy.

Authors:  B T Hill; R D Whelan; H T Rupniak; L A Price
Journal:  Arch Geschwulstforsch       Date:  1981

7.  Cytotoxicity of adriamycin in MGH-U1 cells grown as monolayer cultures, spheroids, and xenografts in immune-deprived mice.

Authors:  C Erlichman; D Vidgen
Journal:  Cancer Res       Date:  1984-11       Impact factor: 12.701

8.  Chemosensitivity of established human bladder carcinoma cell lines in vitro.

Authors:  H Hisazumi; K Nakajima; T Uchibayashi
Journal:  Gan       Date:  1983-02

9.  In vitro chemosensitivity of human bladder cancer.

Authors:  L M Weisenthal; A O Lalude; J B Miller
Journal:  Cancer       Date:  1983-04-15       Impact factor: 6.860

10.  Comparison of the cytotoxic activities of chemotherapeutic drugs using a human bladder cancer cell line.

Authors:  P J Hepburn; R T Oliver; P A Riley; B T Hill; J R Masters
Journal:  Urol Res       Date:  1985
View more
  7 in total

1.  A new mathematical pharmacodynamic model of clonogenic cancer cell death by doxorubicin.

Authors:  Jan Lankelma; Rafael Fernández Luque; Henk Dekker; Jaap van den Berg; Bob Kooi
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-07-18       Impact factor: 2.745

2.  Two-mechanism peak concentration model for cellular pharmacodynamics of Doxorubicin.

Authors:  Ardith W El-Kareh; Timothy W Secomb
Journal:  Neoplasia       Date:  2005-07       Impact factor: 5.715

Review 3.  Recurrence mechanisms of non-muscle-invasive bladder cancer - a clinical perspective.

Authors:  Jeremy Yuen-Chun Teoh; Ashish M Kamat; Peter C Black; Petros Grivas; Shahrokh F Shariat; Marek Babjuk
Journal:  Nat Rev Urol       Date:  2022-03-31       Impact factor: 16.430

4.  Sustained intravesical drug delivery using thermosensitive hydrogel.

Authors:  Pradeep Tyagi; Zhenhua Li; Michael Chancellor; William C De Groat; Naoki Yoshimura; Leaf Huang
Journal:  Pharm Res       Date:  2004-05       Impact factor: 4.200

5.  Pharmacokinetics of UGN-101, a mitomycin-containing reverse thermal gel instilled via retrograde catheter for the treatment of low-grade upper tract urothelial carcinoma.

Authors:  Ahmad Shabsigh; Nir Kleinmann; Angela B Smith; Douglas Scherr; Elyse Seltzer; Mark Schoenberg; Seth P Lerner
Journal:  Cancer Chemother Pharmacol       Date:  2021-03-07       Impact factor: 3.333

6.  Antiproliferation and cell apoptosis inducing bioactivities of constituents from Dysosma versipellis in PC3 and Bcap-37 cell lines.

Authors:  Xiaoqiang Xu; Xiuhong Gao; Linhong Jin; Pinaki S Bhadury; Kai Yuan; Deyu Hu; Baoan Song; Song Yang
Journal:  Cell Div       Date:  2011-06-15       Impact factor: 5.130

7.  Treating acute cystitis with biodegradable micelle-encapsulated quercetin.

Authors:  Bi Lan Wang; Xiang Gao; Ke Men; Jinfeng Qiu; Bowen Yang; Ma Ling Gou; Mei Juan Huang; Ning Huang; Zhi Yong Qian; Xia Zhao; Yu Quan Wei
Journal:  Int J Nanomedicine       Date:  2012-05-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.